Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Tuesday's Mad Money on CNBC:
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
The $639 million deal marks the the third purchase for Brent Saunders since early August.
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said today that trials of their cholesterol drug Praulent met targets.
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.